NCT04347629

Brief Summary

The overall objective of this study is to reduce the burden of chronic kidney disease (CKD) and its consequences for an aging U.S. population. To accomplish this, the investigators propose to conduct a multi-center randomized trial of an advance care planning (ACP) video intervention (vs. usual care) among older patients with CKD.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
456

participants targeted

Target at P75+ for not_applicable

Timeline
11mo left

Started Jun 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

9 active sites

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress84%
Jun 2021May 2027

First Submitted

Initial submission to the registry

April 11, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

April 15, 2020

Completed
1.2 years until next milestone

Study Start

First participant enrolled

June 21, 2021

Completed
4.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2026

Completed
1.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2027

Expected
Last Updated

March 17, 2026

Status Verified

March 1, 2026

Enrollment Period

4.8 years

First QC Date

April 11, 2020

Last Update Submit

March 13, 2026

Conditions

Keywords

video decision aidvideo declarationaging population

Outcome Measures

Primary Outcomes (1)

  • Change in Advance Care Planning (ACP) in Electronic Health Record (EHR) Documentation

    Documentation in the electronic health record reflecting an ACP conversation (any of the following: completion of advance directive or physician order for life sustaining treatment (POLST); code status documentation; provider note reflecting ACP discussion).

    Baseline, 12 months

Secondary Outcomes (9)

  • Change in ACP Engagement

    baseline, 12 months

  • Change in ACP Preferences

    Baseline, 12 months

  • Change in ACP Conversations

    Baseline, 12 months

  • Change in Kidney Disease (KD) Specific Quality of Life (QOL)

    Baseline, 12 months

  • Change in Health Related Quality of Life (QoL)

    Baseline, 12 months

  • +4 more secondary outcomes

Study Arms (2)

Usual Care

NO INTERVENTION

Usual clinical care

Video Decision Aid

EXPERIMENTAL

The video intervention consists of a video decision aid along with a video declaration (ViDec), which is recorded by the patient. The video decision aid explores ACP options for medical care for end-stage renal disease (ESRD) and reviews hemodialysis, peritoneal dialysis, as well as medical management without dialysis; it also reviews cardiopulmonary resuscitation (CPR). Patients will also audio- or video-record their preferences using a tablet.

Behavioral: Advance Care Planning Video Decision Aid

Interventions

The video decision aid explores ACP options for medical care for end-stage renal disease (ESRD) and reviews hemodialysis, peritoneal dialysis, as well as medical management without dialysis; it also reviews cardiopulmonary resuscitation (CPR). Patients will also audio- or video-record their preferences using a tablet.

Video Decision Aid

Eligibility Criteria

Age65 Years+
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)

You may qualify if:

  • Patients age ≥70 are eligible if they have EITHER Advanced CKD defined as ONE eGFR value ≤ 30 ml/min/1.73m2 in the past 12 months NOT determined to be a result of AKI OR Have a diagnosis of CKD and less than a two-year prognosis from any cause, defined by the clinician answering "NO" to the Surprise Question ("Would you be surprised if this patients died in the next two years?")
  • Patients age 65-69 are eligible if they have BOTH Advanced CKD defined as ONE eGFR value ≤ 30 ml/min/1.73m2 NOT determined to be a result of AKI AND Have less than a two-year prognosis, defined by the clinician answering "NO" to the Surprise Question ("Would you be surprised if this patients died in the next two years?")
  • Patients who have not had a nephrology visit in the past 12 months can be recruited from non-Nephrology Clinics per the above eligibility criteria

You may not qualify if:

  • listed for kidney transplantation or previous transplant recipient
  • already on or previously on dialysis (including emergent dialysis)
  • new patient visit
  • visually impaired beyond 20/200 corrected
  • psychological state not appropriate for ACP discussions as determined by the primary nephrologist
  • cognitive impairment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (9)

VA Palo Alto Health Care System

Palo Alto, California, 94034-1290, United States

Location

Stanford University

Palo Alto, California, 94034, United States

Location

Brigham & Women's Hospital

Boston, Massachusetts, 02115-6110, United States

Location

Massachusetts General Hospital

Boston, Massachusetts, 02118-2908, United States

Location

Boston Medical Center

Boston, Massachusetts, 02118, United States

Location

Renal and Transplant Associates of New England, PC

Springfield, Massachusetts, 01107-1381, United States

Location

The University of New Mexico Health Sciences Center

Albuquerque, New Mexico, 87131-0001, United States

Location

University of Pennsylvania

Philadelphia, Pennsylvania, 19104-6205, United States

Location

University of Washington

Seattle, Washington, 98195-9472, United States

Location

Related Publications (1)

  • Eneanya ND, Lakin JR, Paasche-Orlow MK, Lindvall C, Moseley ET, Henault L, Hanchate AD, Mandel EI, Wong SPY, Zupanc SN, Davis AD, El-Jawahri A, Quintiliani LM, Chang Y, Waikar SS, Bansal AD, Schell JO, Lundquist AL, Tamura MK, Yu MK, Unruh ML, Argyropoulos C, Germain MJ, Volandes A. Video Images about Decisions for Ethical Outcomes in Kidney Disease (VIDEO-KD): the study protocol for a multi-centre randomised controlled trial. BMJ Open. 2022 Apr 8;12(4):e059313. doi: 10.1136/bmjopen-2021-059313.

MeSH Terms

Conditions

Kidney Failure, Chronic

Condition Hierarchy (Ancestors)

Renal Insufficiency, ChronicRenal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Michael Paasche-Orlow, MD, MPH

    Tufts Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 11, 2020

First Posted

April 15, 2020

Study Start

June 21, 2021

Primary Completion

March 31, 2026

Study Completion (Estimated)

May 31, 2027

Last Updated

March 17, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will share

The phenotypic data associated with enrolled participants will be shared by depositing these data in the Open Science Framework data repository. Additional data documentation and de-identified IPD including demographics, diagnoses, and outcomes will be deposited. Resources such as study protocols and statistical analysis codes will also be made available.

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
Time Frame
Outcome data will be deposited into Open Science Framework repository as soon as possible but no later than within one year of the completion of the funded project period for the parent award or upon acceptance of the data for publication, or public disclosure of a submitted patent application, whichever is earlier. Data will remain available for a period of 5 years.
Access Criteria
Data and supporting information will be shared with investigators working in accordance to guidelines set by the data repository. Meta-analysis data and associated phenotypic data, along with data content, format, and organization, will be made available to investigators through the Open Science Framework data repository.

Locations